| Trial ID: | L4405 |
| Source ID: | NCT01573949
|
| Associated Drug: |
Metformin
|
| Title: |
A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01573949/results
|
| Conditions: |
Diabetes|Heart Failure
|
| Interventions: |
DRUG: Metformin
|
| Outcome Measures: |
Primary: Health-Related Quality of Life (HRQoL), HRQoL as assessed by the Minnesota Living With Heart Failure Questionnaire (MLHFQ) The MLHFQ is a self-administered questionnaire for patients with HF, comprising 21 items rated on six-point Likert scales, representing different degrees of impact of HF on HRQoL, from 0 (none) to 5 (very much). It provides a total score range 0-105. Lower scores indicate better health-related quality of life (HRQoL)., 3 months | Secondary: Glycated Hemoglobin (HbA1c), The HbA1c test measures how much glucose is bound to hemoglobin in the red blood cells. The test shows the average level of glucose in blood for the past 3 months (the average lifespan of red blood cells). If glucose levels have been high over recent weeks, the hemoglobin A1c test will be higher., 3 months|Left Ventricular Ejection Fraction (LVEF), Obtained from Echocardiography, 3 months|Creatinine Level as a Measure of Renal Function, Serum creatinine, 3 months
|
| Sponsor/Collaborators: |
Sponsor: University of California, Los Angeles
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
7
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2011-12
|
| Completion Date: |
2012-12
|
| Results First Posted: |
2020-09-04
|
| Last Update Posted: |
2020-09-04
|
| Locations: |
Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, California, 90095, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01573949
|
